TW593315B - Substituted pyridines and pyridazines with angiogenesis inhibiting activity - Google Patents

Substituted pyridines and pyridazines with angiogenesis inhibiting activity Download PDF

Info

Publication number
TW593315B
TW593315B TW089119700A TW89119700A TW593315B TW 593315 B TW593315 B TW 593315B TW 089119700 A TW089119700 A TW 089119700A TW 89119700 A TW89119700 A TW 89119700A TW 593315 B TW593315 B TW 593315B
Authority
TW
Taiwan
Prior art keywords
methyl
amino
oxy
furo
group
Prior art date
Application number
TW089119700A
Other languages
English (en)
Chinese (zh)
Inventor
Jacques P Dumas
Stephen James Boyer
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of TW593315B publication Critical patent/TW593315B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
TW089119700A 1999-09-28 2000-09-25 Substituted pyridines and pyridazines with angiogenesis inhibiting activity TW593315B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
TW593315B true TW593315B (en) 2004-06-21

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089119700A TW593315B (en) 1999-09-28 2000-09-25 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Country Status (35)

Country Link
EP (1) EP1228063B1 (https=)
JP (1) JP4919567B2 (https=)
KR (3) KR100895571B1 (https=)
CN (3) CN100422173C (https=)
AR (3) AR025752A1 (https=)
AT (1) ATE422494T1 (https=)
AU (1) AU782820B2 (https=)
BG (1) BG65860B1 (https=)
BR (1) BRPI0014382B8 (https=)
CA (1) CA2385817C (https=)
CO (1) CO5200835A1 (https=)
CZ (1) CZ304767B6 (https=)
DE (1) DE60041548D1 (https=)
DO (1) DOP2000000070A (https=)
EE (1) EE05258B1 (https=)
ES (1) ES2320525T3 (https=)
GT (1) GT200000158A (https=)
HR (1) HRP20020308A2 (https=)
HU (1) HU230223B1 (https=)
IL (3) IL148880A0 (https=)
MA (1) MA25563A1 (https=)
MX (1) MXPA02003156A (https=)
MY (3) MY135058A (https=)
NO (1) NO20021520L (https=)
NZ (1) NZ518589A (https=)
PA (1) PA8503201A1 (https=)
PE (1) PE20010607A1 (https=)
PL (1) PL205957B1 (https=)
RS (1) RS50369B (https=)
RU (1) RU2260008C2 (https=)
SK (1) SK287417B6 (https=)
TW (1) TW593315B (https=)
UA (1) UA75053C2 (https=)
WO (1) WO2001023375A2 (https=)
ZA (1) ZA200202760B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
ATE421324T1 (de) * 2003-03-11 2009-02-15 Novartis Ag Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
JPWO2004089412A1 (ja) * 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 特異的nad(p)hオキシダーゼ抑制剤
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
EP2010173A1 (en) * 2006-04-15 2009-01-07 Bayer HealthCare AG Compounds for treating pulmonary hypertension
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA
US12421228B2 (en) * 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
WO1996005176A1 (en) * 1994-08-09 1996-02-22 Eisai Co., Ltd. Fused pyridazine compound
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf

Also Published As

Publication number Publication date
MY143580A (en) 2011-05-31
GT200000158A (es) 2002-03-16
HK1091818A1 (zh) 2007-01-26
IL193367A (en) 2011-03-31
KR100890473B1 (ko) 2009-03-26
AU1569601A (en) 2001-04-30
KR20080086547A (ko) 2008-09-25
KR20080091505A (ko) 2008-10-13
ES2320525T3 (es) 2009-05-25
KR100895571B1 (ko) 2009-04-29
PE20010607A1 (es) 2001-07-12
EE05258B1 (et) 2010-02-15
BRPI0014382B8 (pt) 2021-05-25
DOP2000000070A (es) 2002-02-28
CA2385817A1 (en) 2001-04-05
CA2385817C (en) 2010-05-04
EE200200161A (et) 2003-08-15
HRP20020308B1 (https=) 2013-01-31
KR20020038775A (ko) 2002-05-23
CN1769283A (zh) 2006-05-10
RU2260008C2 (ru) 2005-09-10
WO2001023375A3 (en) 2002-05-02
HRP20020308A2 (en) 2004-06-30
KR100895572B1 (ko) 2009-04-29
BR0014382B1 (pt) 2014-04-01
ATE422494T1 (de) 2009-02-15
AR025752A1 (es) 2002-12-11
YU22902A (sh) 2004-12-31
BG106637A (bg) 2003-02-28
WO2001023375A2 (en) 2001-04-05
NO20021520L (no) 2002-05-23
AU782820B2 (en) 2005-09-01
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
HUP0202704A3 (en) 2003-12-29
SK5912002A3 (en) 2003-01-09
MY143377A (en) 2011-05-13
DE60041548D1 (de) 2009-03-26
HK1091819A1 (zh) 2007-01-26
PA8503201A1 (es) 2002-08-26
CN100422172C (zh) 2008-10-01
AR082231A2 (es) 2012-11-21
MXPA02003156A (es) 2002-09-30
CN100422173C (zh) 2008-10-01
UA75053C2 (en) 2006-03-15
RS50369B (sr) 2009-11-10
IL148880A0 (en) 2002-09-12
BG65860B1 (bg) 2010-03-31
EP1228063B1 (en) 2009-02-11
CZ20021444A3 (cs) 2002-08-14
CN1420879A (zh) 2003-05-28
CO5200835A1 (es) 2002-09-27
HUP0202704A2 (hu) 2002-12-28
IL193368A0 (en) 2009-02-11
MA25563A1 (fr) 2002-10-01
HU230223B1 (en) 2015-10-28
PL205957B1 (pl) 2010-06-30
AR082232A2 (es) 2012-11-21
ZA200202760B (en) 2003-10-29
JP2003526632A (ja) 2003-09-09
BR0014382A (pt) 2003-06-24
NZ518589A (en) 2005-03-24
IL193367A0 (en) 2009-02-11
PL366342A1 (en) 2005-01-24
NO20021520D0 (no) 2002-03-26
CZ304767B6 (cs) 2014-10-08
MY135058A (en) 2008-01-31
SK287417B6 (sk) 2010-09-07
CN100374435C (zh) 2008-03-12
IL193368A (en) 2011-05-31
JP4919567B2 (ja) 2012-04-18

Similar Documents

Publication Publication Date Title
TW593315B (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
TW477788B (en) Substituted heteroaromatic compounds and their methods for their preparation and use
US8680139B2 (en) Anti-neoplastic compounds, compositions and methods
KR100226114B1 (ko) 항증식 작용을 가진 퀴나졸린 화합물
US10562912B2 (en) Heterocyclic derivatives and use thereof
JP5216341B2 (ja) 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
TW200914443A (en) Process for preparing substituted quinazolinyl furanaldehyde
TWI301834B (en) Pyrimidone compound and pharmaceutical composition including the same
WO2001087845A2 (en) N-containing heterocyclic compounds and their use as 5-ht antagonists
US20070281936A1 (en) Pyrimidine Compounds as Purine Receptor Antagonist
TW201113272A (en) Novel pyrimidine-and triazine hepcidine antagonists
JPWO2010058846A1 (ja) 4,6−ジアミノニコチンアミド化合物
AU2005317870A1 (en) Pyridine carboxamide derivatives for use as anticancer agents
TW200526593A (en) New pyridazin-3(2H)-one derivatives
WO2006036024A1 (ja) プロトンポンプ阻害薬
TW201302710A (zh) 新穎磺胺基喹啉鐵調素拮抗劑
JP2011507894A (ja) プロリルヒドロキシラーゼ阻害剤
WO2010072166A1 (zh) 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
AU2018226922B2 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
CA2990583A1 (en) 1,4-disubstituted imidazole derivative
TW201040159A (en) Novel compound having 4-pyridylalkylthio group as substituent
CA3093323C (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
KR20020019969A (ko) 혈관신생 억제 활성을 갖는 치환 피리다진 및 융합 피리다진
WO2021104256A1 (zh) 一种杂环衍生物、其药物组合物及用途
JP2022514685A (ja) ペンタミジンの類似体及びその使用

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent